Stock Report

All about this stock under one free report Last Updated: 23-Sep-2026

Stock Rating

Is this stock worth it? Our ratings reveal the truth.

Wealth Insight New Issue

This month’s issue could change how you invest, read now.

Recently Viewed

Alivus Life Sciences Peer Comparison

Stock Card factsheet watchlist-stock-modal share-fund-plan-icon

NSE: GLS | BSE: 543322

₹1,383.10

up-down-arrow ₹8.90 (0.65%)

As on 23-Sep-2026IST

Market cap

info icon

₹16,987 Cr

Revenue (TTM)

info icon

₹2,590 Cr

P/E Ratio

info icon

28.2

P/B Ratio

info icon

4.9

Div. Yield

info icon

0.4 %

Edit peer-selector-edit
Alivus Life Sciences Emcure Pharmaceuticals Neuland Lab Concord Biotech Sudeep Pharma
Market cap (₹ Cr)
 16,987 37,680 28,903 16,312 13,554
Revenue (₹ Cr)
 2,590 9,683 2,372 1,108 676
Net Profit (₹ Cr)
 603.02 1,018.97 497.77 270.18 183.60
Net Margin (%)
 22.63 10.47 20.72 23.29 26.06
RoE (%)
 19.61 21.30 28.49 14.45 22.72
Price to Earnings
 28.17 37.26 58.06 59.23 74.21
Price-To-Book
 4.87 7.20 14.30 7.87 14.67

Income Statement (₹ Cr)

Alivus Life Sciences Emcure Pharmaceuticals Neuland Lab Concord Biotech Sudeep Pharma
Operating Revenue arrow
2,590.40 9,683.45 2,371.81 1,108.39 675.61
Total Income arrow
2,664.23 9,730.84 2,402.61 1,159.90 704.48
Total Expenditure arrow
1,753.71 7,739.53 1,608.91 720.01 442.67
EBITDA arrow
836.69 1,943.92 762.90 388.38 232.94
Depreciation arrow
78.88 425.10 98.11 74.78 15.56
EBIT arrow
757.81 1,518.82 664.79 313.60 217.38
Interest arrow
5.43 148.45 26.33 0.26 7.96
Other Income arrow
73.83 47.39 30.80 51.50 28.87
Exceptional Items arrow
-25.66 -27.85 0.00 -3.28 0.00
Profit before Tax arrow
800.55 1,389.91 669.26 361.56 238.30
Provision for Tax arrow
197.53 370.94 171.48 91.39 54.69
Profit after Tax arrow
603.02 1,018.97 497.77 270.18 183.60

Liabilities (₹ Cr)

Alivus Life Sciences Emcure Pharmaceuticals Neuland Lab Concord Biotech Sudeep Pharma
Shareholder's Funds arrow
3,332.13 4,950.03 1,874.47 2,017.06 883.34
Minority Interest arrow
0.00 -7.58 0.00 2.51 -0.97
Non-Current Liabilities arrow
142.73 723.57 345.47 50.51 74.82
Current Liabilities arrow
508.04 3,912.24 710.20 169.08 201.96
Total Liabilities arrow
4,157.10 9,514.48 2,930.14 2,231.79 1,174.38

Assets (₹ Cr)

Alivus Life Sciences Emcure Pharmaceuticals Neuland Lab Concord Biotech Sudeep Pharma
Non-Current Assets arrow
1,321.38 3,392.16 1,290.62 957.22 477.92
Current Assets arrow
2,649.36 5,612.10 1,483.13 1,250.11 623.97
Total Assets arrow
4,157.10 9,514.48 2,930.14 2,231.79 1,174.38
Total Debt* arrow
0.00 1,204.08 196.61 0.00 148.29
Net Current Assets arrow
2,141.33 1,699.86 772.93 1,081.04 422.01
Contingent Liabilities arrow
4.82 258.92 13.18 3.76 --

Cashflow (₹ Cr)

Alivus Life Sciences Emcure Pharmaceuticals Neuland Lab Concord Biotech Sudeep Pharma
Cash From Operating Activities arrow
565.41 943.55 346.68 266.88 69.55
Cash Flow from Investing Activities arrow
-570.15 -1,193.06 -423.73 -142.72 -330.93
Cash from Financing Activities arrow
-64.34 343.43 20.98 -112.88 247.29
Net Cash Inflow / Outflow arrow
-69.08 93.92 -56.08 11.28 -14.09

Ratios

Profitability Ratios

 Alivus Life Sciences Emcure Pharmaceuticals Neuland Lab Concord Biotech Sudeep Pharma
ROCE (%) arrow
24.61 25.25 27.50 18.04 28.50
ROE (%) arrow
19.61 21.30 28.49 14.45 22.72
ROA (%) arrow
16.31 11.42 19.48 12.66 31.25
EBIT Margin (%) arrow
29.25 15.68 28.03 28.29 32.18
Net Margin (%) arrow
22.63 10.47 20.72 23.29 26.06
Cash Profit Margin (%) arrow
0.00 0.00 0.00 0.00 0.00

Growth Ratios

 Alivus Life Sciences Emcure Pharmaceuticals Neuland Lab Concord Biotech Sudeep Pharma
Revenue Growth (%) arrow
7.93 18.36 78.33 -6.72 23.56
EBIT Growth (%) arrow
19.88 30.43 303.07 -26.64 12.00
Net Profit Growth (%) arrow
21.66 32.39 182.61 -24.38 20.07
EPS Growth (%) arrow
25.42 36.68 277.72 -21.99 50.65
Book Value Growth (%) arrow
18.43 11.36 22.95 11.27 79.97

Valuation Ratios

 Alivus Life Sciences Emcure Pharmaceuticals Neuland Lab Concord Biotech Sudeep Pharma
Price / Earnings arrow
27.11 36.29 58.07 57.64 71.26
Price / Book Value arrow
4.84 7.17 14.30 7.72 14.66
Dividend Yield (%) arrow
0.36 0.18 0.15 0.49 0.13
EV/EBITDA arrow
19.24 19.82 37.68 40.16 58.27
Market Cap (₹ Cr) arrow
11,956.86 30,257.56 15,412.11 10,627.92 6,690.53

Solvency Ratios

 Alivus Life Sciences Emcure Pharmaceuticals Neuland Lab Concord Biotech Sudeep Pharma
Debt to Equity arrow
0.00 0.05 0.09 0.00 0.04
Short term debt to equity ratio arrow
-- 0.16 -- -- 0.12
Current Ratio arrow
5.21 1.43 2.09 7.39 3.09
Quick Ratio arrow
3.85 0.82 1.37 5.46 2.02
Interest Coverage arrow
148.49 10.36 26.41 1,386.30 30.94

Operating Efficiency Ratios

 Alivus Life Sciences Emcure Pharmaceuticals Neuland Lab Concord Biotech Sudeep Pharma
Debtors to sales (%) arrow
41.42 26.46 22.82 41.52 33.68
Asset Turnover arrow
0.70 1.09 0.93 0.52 1.15
Receivable days arrow
144.58 88.68 77.32 169.86 115.16
Inventory Days arrow
96.67 84.11 80.83 97.92 96.15
Payable days arrow
135.45 176.65 125.94 159.68 106.08
Cash Conversion Cycle arrow
105.80 -3.86 32.22 108.11 105.23
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...
loading...